CN103110640A - Pharmaceutical composition of injection ceftizoxime sodium and compound amino acid injection - Google Patents
Pharmaceutical composition of injection ceftizoxime sodium and compound amino acid injection Download PDFInfo
- Publication number
- CN103110640A CN103110640A CN2013100447311A CN201310044731A CN103110640A CN 103110640 A CN103110640 A CN 103110640A CN 2013100447311 A CN2013100447311 A CN 2013100447311A CN 201310044731 A CN201310044731 A CN 201310044731A CN 103110640 A CN103110640 A CN 103110640A
- Authority
- CN
- China
- Prior art keywords
- injection
- amino acid
- sodium
- acid compound
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a pharmaceutical composition of injection ceftizoxime sodium and compound amino acid injection and in particular relates to combined application package. The pharmaceutical composition includes injection ceftizoxime sodium and compound amino acid injection. During a using process, the injeciton ceftizoxime sodium is dropped to the compound amino acid injection for intravenous infusion of 30 minutes to 2 hours. For the compatibility mixing of the injection ceftizoxime sodium and the compound amino acid injection, the combined application package disclosed by the invention is used for simplifying the steps and improving the safety. Moreover, the stability of the ceftizoxime sodium is greatly facilitated, and the clinical application quality and the bioavailability of the medicine are improved.
Description
Technical field
The present invention relates to the pharmaceutical composition of a kind of ceftiaoxline sodium for injection and Amino Acid Compound Injection, be specifically related to the Combination application packing of the formulated sterile solution for injection of a kind of ceftiaoxline sodium for injection and 18 kinds of crystalline amino acids and xylitol, belong to medical technical field.
Background technology
Ceftizoxime sodium is third generation cephalosporin, has broad-spectrum antibacterial action, and is stable to the wide spectrum beta lactamase of most gram positive bacterias and gram-negative bacteria generation.Ceftizoxime sodium has good antibacterial action to hemophilus influenza and Neisseria gonorrhoeae.
The ceftiaoxline sodium for injection mechanism of action is for the biosynthesis by the anti-bacteria cell wall mucopeptide reaches bactericidal action, is applicable to meningitis and Simple gonorrhea due to lower respiratory infection, urinary tract infection, abdominal cavity infection, pelvic infection, septicemia, skin soft-tissue infection, bone and the infection of joint, streptococcus pneumoniae or the hemophilus influenza due to sensitive organism.
Aminoacid for human body synthetic protein and other tissue provide nitrogenous source, is the base substance of keeping the human life.Aminoacid is except providing nitrogenous source for synthetic protein, part can be used as the energy supply material through oxidation Decomposition, another a small amount of aminoacid can also transform and become some biological active substanceies, thereby keeps the function of some tissues and organ, and each seed amino acid can be transported between individual tissue by blood.To guarantee the amino acid metabolism in tissue.Human normal plasma's amino acid concentration is not high, total concentration be about 2 millimoles/liter, children's in cell is lower for the overwhelming majority, may be fast with children growth, aminoacid take in organize more relevant.Therefore, children's should be higher than the adult to the aminoacid intake.
Amino Acid Compound Injection participates in the anabolism of protein in the situation that the Power supply abundance can enter histiocyte, obtain positive nitrogen balance, and generate the biological active substanceies such as enzyme, hormone, antibody, structural protein, and promote organization healing, recover normal physiological function.
Amino Acid Compound Injection is used for that muscle catabolism under the stress state such as large-area burns, wound and severe infections is hyperfunction, the patient's of digestive system function obstacle, nutrition deterioration and immunologic function degression nutritional support, also be used for patients after surgery, improve its nutritional status.Be used for the patient that the aminoacid such as protein Deficiency of Intake, malabsorption can not satisfy the organism metabolism needs.Also be used for improving the nutriture of patients after surgery.
In addition, prior art is only mentioned ceftiaoxline sodium for injection in operation instructions can use slow intravenous injection after water for injection, sodium chloride injection, 5% glucose injection dissolving, also can be added in 10% glucose injection, electrolyte injection or amino acid injection iv drip 30 minutes-2 hours.Need to buy respectively use in conjunction in clinical use, not ceftiaoxline sodium for injection and Amino Acid Compound Injection assembly packaging appear on market and medical institutions in.
The applicant offers medical institutions and market with ceftiaoxline sodium for injection of the present invention and Amino Acid Compound Injection with the form of assembly packaging, not only greatly improved ease of use and the drug safety of medical institutions, and the stability of each drug alone has been of great benefit to; More importantly by adding xylitol to obtain unforeseeable clinical practice quality and the bioavailability of using simultaneously ceftiaoxline sodium for injection and amino acid injection that improved in Amino Acid Compound Injection.
Summary of the invention
In order to overcome the series of problems that exists in prior art, the inventor has creatively found employing amino acid Xylitol injection and ceftiaoxline sodium for injection compatibility use in conjunction, being about to the formulated sterile solution for injection dissolving of the ceftiaoxline sodium for injection of independent packaging and 18 kinds of crystalline amino acids and xylitol mixes and inputs afterwards in body, the effect that not only has broad-spectrum antiseptic, but also treat simultaneously the amino acids nutritional supplementation.
One of purpose of the present invention provides a kind of new ceftizoxime sodium and the pharmaceutical composition of amino acid, and wherein, ceftizoxime sodium is powder ampoule agent for injection, and amino acid is the formulated sterile solution for injection of 18 kinds of crystalline amino acids and xylitol.
One of purpose of the present invention, the Combination application packing of a kind of ceftiaoxline sodium for injection and Amino Acid Compound Injection is provided, wherein, ceftizoxime sodium is powder ampoule agent for injection, and amino acid is the formulated sterile solution for injection of 18 kinds of crystalline amino acids and xylitol.
Combination application packing provided by the invention, usage is for to be added in the Amino Acid Compound Injection iv drip 30 minutes-2 hours with ceftiaoxline sodium for injection.
More importantly, the xylitol in Amino Acid Compound Injection helps to improve the absorption of ceftizoxime sodium medicine also unexpectedly, makes it have the effect that postpones absorption, and curative effect is more obvious, and this is innovative point of the present invention place.
Combination application packing specification provided by the invention is that ceftiaoxline sodium for injection is with C
13H
13N
5O
5S
2Meter 0.5-4.0g, Amino Acid Compound Injection 50-1000ml.
As the present invention's one preferred embodiment, packing specification of the present invention is that ceftiaoxline sodium for injection is with C
13H
13N
5O
5S
2Meter 0.5-4.0g, Amino Acid Compound Injection 100-500ml.
Ceftiaoxline sodium for injection of the present invention is made by the packing of ceftizoxime sodium aseptic powder, perhaps adds appropriate excipient lyophilization by ceftizoxime sodium and makes.
As one of specific embodiment, concrete component and consumption are as follows:
The present invention also provides a kind of preparation method of ceftiaoxline sodium for injection, and concrete steps are:
The ceftizoxime sodium sterilized powder is sent between packing (packing post ambient temperature is 18 ℃～26 ℃, and relative humidity is below 65%), the debugging racking machine, regulate step number and mix up loading amount, make loading amount reach the scope of regulation, then be sub-packed in low Pyrex control injection bottle made, press full plug, roll lid.
Perhaps, after ceftizoxime sodium and appropriate excipient dissolving, packing, lyophilization, lid is rolled in tamponade.
Amino Acid Compound Injection of the present invention is the formulated sterile water solution of 18 kinds of crystalline amino acids and xylitol, concrete component comprises arginine hydrochloride 2.89g, histidine monohydrochloride 2.46g, leucine 3.79g, isoleucine 1.70g, lysine hydrochloride 3.33g, phenylalanine 2.83g, threonine 1.97g, valine 1.36g, methionine 1.06g, tryptophan 0.39g, glycine 3.24g, alanine 1.88g, proline 1.00g, tyrosine 0.11g, serine 0.67g, cysteine hydrochloride 0.44g, Aspartic Acid 1.15g, glutamic acid 1.97g, sodium sulfite 0.5g, xylitol 50g, water for injection adds to 1000ml.
The present invention also provides a kind of preparation method of Amino Acid Compound Injection, and concrete steps are:
(1) get approximately approximately 60% water for injection of full dose and boil and add appropriate xylitol to make dissolving, then add approximately 0.15%(g/ml) active carbon boiled 20 minutes, return the filter decolouring after 20 minutes filter enter rare filling of joining.
(2) in dilute preparing tank, filter passes into nitrogen after entering xylitol liquid immediately, what add simultaneously other approximately full dose 40% uses 0.15(g/ml again) active carbon boils 20 minutes pretreated water for injection of absorption and the merging of xylitol liquid, opens when cooling water makes amalgamation liquid be cooled to 60 ℃ to begin to feed intake.
(3) first the antioxidant sodium sulfite is divided into halves, a copy of it antioxidant is dropped in amalgamation liquid, then by above-mentioned formula order, each aminoacid is dropped into one by one and make dissolving, should control temperature during to tryptophan approximately can drop into below 50 ℃, aminoacid feeds intake complete, adds another part antioxidant and cysteine hydrochloride.
(4) slowly adding to regulate pH value 5.5-7.0 with about 10% caustic lye of soda, add adding to the full amount of water for injection, add 0.15%(g/ml) active carbon stirs decolouring 20 minutes, circulating filtration 30 minutes.
(5) filter qualified to visible foreign matters after, fill, sealing, sterilization and get final product.
The present invention also provides the Combination application of a kind of ceftiaoxline sodium for injection and Amino Acid Compound Injection to be packaged in the application for preparing in treatment amino acids nutritional supplementation medicine and extensive pedigree antibiotic, has the human body protein of promotion Metabolism of Normal, correct negative nitrogen balance, replenish protein, accelerating wound provides the effect of energy and essential amino acids for body.In addition, this product essential amino acids meets the Vuj-N formula proportion, and non essential amino acid meets Albumin's pattern.The ratio of essential amino acids and non essential amino acid is 1.04:1, and every seed amino acid easily is effectively used to the synthetic of human body protein, and its bioavailability is high.The contained xylitol of this product can enter the cell interior without insulin, and the formation of tool inhibition ketoboidies, saves protein, improves rate of ultilization of amino acid, and promotes the effect that hepatic glycogen is accumulated, and carbohydrate metabolism is had no adverse effect, and has no to cause the metabolic complication.
Description of drawings
Accompanying drawing 1 is the four assembly 5 intravenous blood drug level of solution and the graph of relation of time;
The specific embodiment
Embodiment 1The preparation of ceftiaoxline sodium for injection
Prescription:
Preparation process:
(1) with ceftizoxime sodium sterilized powder 500g(with C
13H
13N
5O
5S
2Meter) send between packing (packing post ambient temperature is 18 ℃～26 ℃, and relative humidity is 65% below), debug racking machine, regulate step number and mix up loading amount, make loading amount reach the scope of regulation, then be sub-packed in low Pyrex control injection bottle made, press full plug, roll lid.
(2) with ceftizoxime sodium sterilized powder 1000g(with C
13H
13N
5O
5S
2Meter) send between packing (packing post ambient temperature is 18 ℃～26 ℃, and relative humidity is 65% below), debug racking machine, regulate step number and mix up loading amount, make loading amount reach the scope of regulation, then be sub-packed in low Pyrex control injection bottle made, press full plug, roll lid.
Embodiment 2The preparation of Amino Acid Compound Injection
Prescription:
Arginine hydrochloride 289g alanine 188g
Histidine monohydrochloride 246g proline 100g
Leucine 379g tyrosine 11g
Isoleucine 170g serine 67g
Lysine hydrochloride 333g cysteine hydrochloride 44g
Phenylalanine 283g Aspartic Acid 115g
Threonine 197g glutamic acid 197g
Valine 136g sodium sulfite 50g
Methionine 106g xylitol 5000g
Tryptophan 039g water for injection adds to 100L
Glycine 324g
Preparation process:
(1) get 60L water for injection and boil and add the 5000g xylitol to make dissolving, then add the 150g active carbon to boil 20 minutes, return the filter decolouring after 20 minutes filter enter rare filling of joining.
(2) in dilute preparing tank, filter passes into nitrogen after entering xylitol liquid immediately, what add simultaneously other 40L boils 20 minutes pretreated water for injection of absorption and the merging of xylitol liquid with the 150g active carbon again, opens when cooling water makes amalgamation liquid be cooled to 60 ℃ to begin to feed intake.
(3) first antioxidant sodium sulfite 50g is divided into halves, a copy of it antioxidant 25g is dropped in amalgamation liquid, then press above-mentioned formula order with arginine hydrochloride 289g, histidine monohydrochloride 246g, leucine 379g, isoleucine 170g, lysine hydrochloride 333g, phenylalanine 283g, threonine 197g, valine 136g, methionine 106g, tryptophan 39g, glycine 324g, alanine 188g, proline 100g, tyrosine 11g, serine 67g, Aspartic Acid 115g, glutamic acid 197g drops into one by one and makes dissolving, should control temperature during to tryptophan approximately can drop into below 50 ℃, aminoacid feeds intake complete, add another part antioxidant 25g and cysteine hydrochloride 44g,
(4) slowly add to regulate pH value 6.3 with about 10% caustic lye of soda, add adding to the full amount of water for injection, add the 150g active carbon to stir decolouring 20 minutes, circulating filtration 30 minutes.
(5) filter qualified to visible foreign matters after, fill, 100ml/ bottle or 250ml/ bottle or 500ml bottle, sealing, 121 ℃ of pressure sterilizings 20 minutes, and get final product.
Embodiment 3The preparation of assembly packaging medicine
Combination 1: ceftiaoxline sodium for injection 0.5g and Amino Acid Compound Injection 100ml.
Combination 2: ceftiaoxline sodium for injection 0.5g and Amino Acid Compound Injection 250ml.
Combination 3: ceftiaoxline sodium for injection 1.0g and Amino Acid Compound Injection 250ml.
Combination 4: ceftiaoxline sodium for injection 1.0g and Amino Acid Compound Injection 500ml.
Combination 5: ceftiaoxline sodium for injection 2.0g and Amino Acid Compound Injection 250ml.
Combination 6: ceftiaoxline sodium for injection 2.0g and Amino Acid Compound Injection 500ml.
Combination 7: ceftiaoxline sodium for injection 1.0g and Amino Acid Compound Injection 100ml.
Combination 8: ceftiaoxline sodium for injection 3.0g and Amino Acid Compound Injection 250ml.
Combination 9: ceftiaoxline sodium for injection 3.0g and Amino Acid Compound Injection 500ml.
Combination 10: ceftiaoxline sodium for injection 4.0g and Amino Acid Compound Injection 500ml.
Embodiment 4Stability test
In order to verify that in assembly packaging process of clinical application of the present invention, stability to ceftizoxime sodium is of great benefit to, the ceftiaoxline sodium for injection that we choose embodiment 1 preparation carries out compatibility with following injection to be mixed,
(1) sodium chloride injection lot number: 20120801-1 Qingzhou Yaowang Pharmaceutical Co., Ltd.
(2) 5% glucose injection lot numbers: 20121002-5 Qingzhou Yaowang Pharmaceutical Co., Ltd.
(3) Multiple electrolytes injection lot number: 1206003 Kelun Pharm Ind Co., Ltd., Sichuan
(4) the Amino Acid Compound Injection embodiment of the present invention 2 preparations
Then detect mixed liquor in the related substance situation of change of 0,1,2,4,6 hour ceftizoxime sodium, compare, result is as follows:
Conclusion: can be found out by above result of the test, the Amino Acid Compound Injection compatibility of ceftiaoxline sodium for injection and the embodiment of the present invention 2 preparations mixes, related substance increased minimum in 6 hours, illustrate that stability of solution is better than other three kinds of injection far away, so assembly packaging of the present invention stability to ceftizoxime sodium in clinical use procedure is of great benefit to, and has ensured product quality.
The mensuration of embodiment 5 blood drug level
40 rats are divided into 4 groups at random, wherein the ceftiaoxline sodium for injection of first group of intravenous injection embodiment 1 preparation and the compatibility mixed liquor of commercially available product sodium chloride injection (lot number: 20120801-1, Qingzhou Yaowang Pharmaceutical Co., Ltd.); The ceftiaoxline sodium for injection of second group of intravenous injection embodiment 1 preparation and the compatibility mixed liquor of commercially available product 5% glucose injection (lot number: 20121002-5, Qingzhou Yaowang Pharmaceutical Co., Ltd.); The compatibility mixed liquor of the ceftiaoxline sodium for injection of the 3rd group of intravenous injection embodiment 1 preparation and commercially available product Multiple electrolytes injection (lot number: 1206003, Kelun Pharm Ind Co., Ltd., Sichuan); The compatibility mixed liquor of the Amino Acid Compound Injection of the ceftiaoxline sodium for injection of the 4th group of intravenous injection embodiment 1 preparation and embodiment 2 preparations.With 1.0g ceftizoxime sodium and 250ml injection compatibility, injected dose is the 8ml/kg body weight.Respectively at 0.5h, 1h, 1.5h, 2h, 3h, 6h, 8h, 12h, take a blood sample after administration, blood sample is measured the blood drug level of ceftizoxime sodium after treatment with the HPLC-MS method.Draw the four assembly 5 intravenous blood drug level of solution and the relation curves of time, be shown in accompanying drawing 1.
As shown in Figure 1, in four assembly 5 solution, the 4th group of solution intravenous injection has the following advantages: the blood drug level peak value of ceftizoxime sodium is high, release rate in vivo slows down, distribution time extends in the body circulation, has reached improved delayed release effect, and bioavailability increases.
The mensuration of test example 6 bioavailability
Get 24 rats, body weight (205 ± 10) g, be divided at random 4 groups, wherein the ceftiaoxline sodium for injection of first group of intravenous injection embodiment 1 preparation and the compatibility mixed liquor of commercially available product sodium chloride injection (lot number: 20120801-1, Qingzhou Yaowang Pharmaceutical Co., Ltd.); The ceftiaoxline sodium for injection of second group of intravenous injection embodiment 1 preparation and the compatibility mixed liquor of commercially available product 5% glucose injection (lot number: 20121002-5, Qingzhou Yaowang Pharmaceutical Co., Ltd.); The compatibility mixed liquor of the ceftiaoxline sodium for injection of the 3rd group of intravenous injection embodiment 1 preparation and commercially available product Multiple electrolytes injection (lot number: 1206003, Kelun Pharm Ind Co., Ltd., Sichuan); The compatibility mixed liquor of the Amino Acid Compound Injection of the ceftiaoxline sodium for injection of the 4th group of intravenous injection embodiment 1 preparation and embodiment 2 preparations.Dosage is ceftiaoxline sodium for injection 1.0g and injects liquid 250ml.After administration, 2h took a blood sample 48 hours.Adopt high performance liquid chromatography to detect the blood drug level of ceftizoxime sodium, be specially: be filler with octadecylsilane chemically bonded silica; So that pH3.6 buffer (get citric acid 1.42g, sodium hydrogen phosphate 2.31g is dissolved in water and is diluted to 1000ml)-acetonitrile (9:1) is mobile phase; The detection wavelength is 254nm.Take ceftizoxime reference substance 5mg, put in the 10ml bottle, add 0.1mol/L sodium hydroxide solution 1ml, placed 30 minutes, be diluted to scale with the pH7.0 phosphate buffer, shake up, must contain the mixed solution of about 4% ceftizoxime alkaline degradation thing (its relative retention time approximately 0.8), get 20 μ l injection liquid chromatographies, record chromatogram, ceftizoxime peak retention time is about 8 minutes, and ceftizoxime peak and its relative retention time approximately separating degree at 0.8 alkaline degradation thing peak, place should be not less than 3.0.Sample thief adds the pH7.0 phosphate buffer and is diluted to scale, shakes up, and precision measures 20 μ l injection liquid chromatographies, records chromatogram; By the content of external standard method with ceftizoxime in the calculated by peak area test sample.Use software 3p87 and WT1.4 to carry out data analysis, relevant pharmacokinetic parameters result such as following table.
can be found out by above experimental data, in four assembly 5 solution, the 4th group of solution is that the compatibility mixed liquor intravenous injection of ceftiaoxline sodium for injection and the Amino Acid Compound Injection of embodiment 2 preparations of the embodiment of the present invention 1 preparation is than other three assembly, 5 mixed liquor intravenous injections, bioavailability improves greatly, proved absolutely that the present invention is with the intravenous benefit of the assembly packaging of ceftiaoxline sodium for injection and Amino Acid Compound Injection, the delayed release of xylitol, embodying of sorbefacient successful, make injection improve widely bioavailability, obtained unexpected technical effect.
Industrial applicibility
Below through the specific embodiment and the embodiment the present invention is had been described in detail; but should understand; these explanations do not consist of any restriction to scope of the present invention; in the case of without departing from the spirit and scope of protection of the present invention; can carry out multiple modification, improvement and replacement to technical solutions and their implementation methods of the present invention, these are all because falling within the scope of protection of the present invention.
Each list of references of mentioning in the application or quoting, which is hereby incorporated by reference.
Claims (2)
1. a pharmaceutical composition that comprises ceftiaoxline sodium for injection and Amino Acid Compound Injection, is characterized in that ceftizoxime sodium is powder ampoule agent for injection, and Amino Acid Compound Injection is the formulated sterile solution for injection of 18 kinds of crystalline amino acids and xylitol; Wherein, ceftiaoxline sodium for injection by ceftizoxime sodium with C
13H
13N
5O
5S
2Meter 0.5-4.0g makes; Amino Acid Compound Injection is by arginine hydrochloride 2.89g, histidine monohydrochloride 2.46g, leucine 3.79g, isoleucine 1.70g, lysine hydrochloride 3.33g, phenylalanine 2.83g, threonine 1.97g, valine 1.36g, methionine 1.06g, tryptophan 0.39g, glycine 3.24g, alanine 1.88g, proline 1.00g, tyrosine 0.11g, serine 0.67g, cysteine hydrochloride 0.44g, Aspartic Acid 1.15g, glutamic acid 1.97g, sodium sulfite 0.5g, xylitol 50g, water for injection adds to 1000ml and makes.
2. according to 1 described pharmaceutical composition, it is characterized in that this pharmaceutical composition can pack for Combination application.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310044731.1A CN103110640B (en) | 2013-02-04 | 2013-02-04 | Pharmaceutical composition of injection ceftizoxime sodium and compound amino acid injection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310044731.1A CN103110640B (en) | 2013-02-04 | 2013-02-04 | Pharmaceutical composition of injection ceftizoxime sodium and compound amino acid injection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103110640A true CN103110640A (en) | 2013-05-22 |
| CN103110640B CN103110640B (en) | 2014-04-16 |
Family
ID=48409041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310044731.1A Expired - Fee Related CN103110640B (en) | 2013-02-04 | 2013-02-04 | Pharmaceutical composition of injection ceftizoxime sodium and compound amino acid injection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103110640B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103393689A (en) * | 2013-08-02 | 2013-11-20 | 海南灵康制药有限公司 | Pharmaceutical composition of cefotiam hydrochloride for injection and compound amino acid injection |
| CN103446158A (en) * | 2013-09-06 | 2013-12-18 | 海南美兰史克制药有限公司 | Pharmaceutical composition of cefmenoxime hydrochloride and pediatric compound amino acid injection |
| CN103446056A (en) * | 2013-09-05 | 2013-12-18 | 海南美大制药有限公司 | Pharmaceutical composition containing ceftizoxime sodium and pediatric compound amino acid injection (19AA-I) |
| CN103463094A (en) * | 2013-09-04 | 2013-12-25 | 海南美大制药有限公司 | Medicine composition of cefpiramide sodium and infant compound amino acid injection (19AA-I) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101439036A (en) * | 2008-12-22 | 2009-05-27 | 郑飞雄 | Pharmaceutical composition containing 18 kinds of amino acid |
| CN101606910A (en) * | 2009-07-20 | 2009-12-23 | 山东罗欣药业股份有限公司 | A kind of ceftizoxime sodium medicine injectable powder and preparation method thereof, and synthetic method of bulk drug ceftizoxime sodium |
-
2013
- 2013-02-04 CN CN201310044731.1A patent/CN103110640B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101439036A (en) * | 2008-12-22 | 2009-05-27 | 郑飞雄 | Pharmaceutical composition containing 18 kinds of amino acid |
| CN101606910A (en) * | 2009-07-20 | 2009-12-23 | 山东罗欣药业股份有限公司 | A kind of ceftizoxime sodium medicine injectable powder and preparation method thereof, and synthetic method of bulk drug ceftizoxime sodium |
Non-Patent Citations (1)
| Title |
|---|
| 郭静,周学琴: "注射用头孢唑肟钠在复方氨基酸注射液中稳定性的研究", 《现代医院》, vol. 9, no. 9, 30 September 2009 (2009-09-30), pages 60 - 61 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103393689A (en) * | 2013-08-02 | 2013-11-20 | 海南灵康制药有限公司 | Pharmaceutical composition of cefotiam hydrochloride for injection and compound amino acid injection |
| CN103463094A (en) * | 2013-09-04 | 2013-12-25 | 海南美大制药有限公司 | Medicine composition of cefpiramide sodium and infant compound amino acid injection (19AA-I) |
| CN103446056A (en) * | 2013-09-05 | 2013-12-18 | 海南美大制药有限公司 | Pharmaceutical composition containing ceftizoxime sodium and pediatric compound amino acid injection (19AA-I) |
| CN103446056B (en) * | 2013-09-05 | 2014-07-02 | 海南美大制药有限公司 | Pharmaceutical composition containing ceftizoxime sodium and pediatric compound amino acid injection (19AA-I) |
| CN103446158A (en) * | 2013-09-06 | 2013-12-18 | 海南美兰史克制药有限公司 | Pharmaceutical composition of cefmenoxime hydrochloride and pediatric compound amino acid injection |
| CN103446158B (en) * | 2013-09-06 | 2015-01-07 | 海南美兰史克制药有限公司 | Pharmaceutical composition of cefmenoxime hydrochloride and pediatric compound amino acid injection |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103110640B (en) | 2014-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5522877B2 (en) | Moxifloxacin / sodium chloride preparation | |
| CN102429902B (en) | Pharmaceutical composition of alanyl glutamine and compound amino acid | |
| CN103110640B (en) | Pharmaceutical composition of injection ceftizoxime sodium and compound amino acid injection | |
| CN102631665B (en) | Pharmaceutical composition of alanyl glutamine injection and compound amino acid injection | |
| CN101947234A (en) | Preparation method for preparation containing glucosamine and application thereof | |
| CN109432123A (en) | A kind of compound electrolyte glucose injection and preparation method thereof | |
| CN103083322B (en) | Medicinal composition containing injection cefmenoxime hydrochloride and compound amino acid injection | |
| CN102145009A (en) | Octadeca compound amino acid injection and preparation method thereof | |
| UA73316C2 (en) | Pharmaceutical formulations containing benzamide derivative as active ingredient | |
| CN102335114B (en) | Stable ibuprofen arginine injection and preparation method thereof | |
| CN109568277A (en) | Citric acid is preparing application in SC 69124 sodium freeze-dried preparation composition and combinations thereof and preparation method | |
| CN102961397B (en) | Pharmaceutical composition of fat emulsion injection and compound amino acid injection | |
| CN103393689B (en) | Pharmaceutical composition of cefotiam hydrochloride for injection and compound amino acid injection | |
| CN102258507A (en) | Ibuprofen-containing pharmaceutical composition and its preparation method and application | |
| CN103446056B (en) | Pharmaceutical composition containing ceftizoxime sodium and pediatric compound amino acid injection (19AA-I) | |
| CN102008461B (en) | A kind of ibuprofen drug composite for injection | |
| CN103027894A (en) | Ceftazidime composition for injection and preparation method for ceftazidime composition | |
| CN103463094B (en) | Medicine composition of cefpiramide sodium and infant compound amino acid injection (19AA-I) | |
| CN107789365A (en) | The medical composition and its use of various trace elements V | |
| CN102757471B (en) | Novel active cytidine disodium triphosphate compound and pharmaceutical composition thereof | |
| CN103446158B (en) | Pharmaceutical composition of cefmenoxime hydrochloride and pediatric compound amino acid injection | |
| CN102698248B (en) | Medicine composition prepared from alanyl glutamine and compound amino acid by utilizing spray drying method | |
| CN101697973B (en) | Cefathiamidine preparation for injection and preparation method thereof | |
| CN102698247B (en) | Glutamine dipeptide and compound amino acid medicinal composition prepared with solvent crystallization method | |
| CN104922133A (en) | Medicine combination of cefpiramide (sodium) for injection and compound amino acid injection (18AA-V) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: HAINAN SHENGXIN PHARMACEUTICAL TECHNOLOGY CO., LTD Free format text: FORMER OWNER: HAINAN ZHONGYUANTANG MEDICAL TECHNOLOGY CO., LTD. Effective date: 20140402 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 570100 HAIKOU, HAINAN PROVINCE TO: 570311 HAIKOU, HAINAN PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20140402 Address after: 570311 Hainan city of Haikou Province Hong Kong Bamboo Development Zone Xiuying District Road No. 1, building 2, No. 1 West Patentee after: HAINAN SHENGXIN MEDICAL TECHNOLOGY CO., LTD. Address before: 570100, No. 6, No. 168, Haikou Free Trade Zone, Nanhai Avenue, Hainan, Haikou Patentee before: Hainan Zhongyuantang Medical Science & Technology Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140416 Termination date: 20170204 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |